Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Here's another 2-for-1 split coming that has call options written all over it.
Marathon Oil OKs 2-for-1 stock split; raises dividend 20%
By Katherine Hunt
Last Update: 4:22 PM ET Apr 25, 2007
SAN FRANCISCO (MarketWatch) -- Marathon Oil Corp. (MRO : MRO) late Wednesday declared a 2-for-1 stock split, to be distributed in the form of a stock dividend on June 18 to shareholders of record as of May 23. Additionally, the Houston-based company increased its quarterly dividend 20% to 48 cents from 40 cents a share, on a pre-split basis. The dividend is payable on June 11 to shareholders of record as of May 16. On a post-split basis, the new dividend would be 24 cents a share, the company said.
----------------------
G' day Mates,
Aussie
Verylong...Thanks. It helps to be on the right page when dealing with options.
My biggest fault when I started was not knowing how and when to properly use stops. I'm still learning. But, I know one thing for sure, options is the way.
G' day Mate,
Aussie
Verylong...I understand the logic of "...the reason is that earnings are due pre-market tomorrow." when the earnings will in the case of PMTI.
My not understnading came into play with one like ERIC which had their quarterly report out on 3/21 and was the reason I bought the ERIC May 42.5 calls. Good reports usually generate the PPS upward for a couple days. In ERIC's case, unfortunately the PPS went down and I was about to lose two thirds of my purchase price. However, I decided the move downward was going to be short lived and the effects of the report would start to show.
This last week, that is what happen as the May 42.5 calls have now gone above my price of $.30 to %.40. That's where I guess your statement of "The GREATEST percent yield on an option that goes up or down happens the closest month towards expiration. A May 40 call moving higher will appreciate faster than a September 40 call with the same increase in stock price due to being closer in expiration." now comes into play.
Now based on your next statement of "In fact, if there were to have been an April 40 call expiring THIS Friday, it would have been the better buy yesterday, because the percentage increase in price would be much higher than a May 40 given the same increase in stock price." I should make definite plans to sell the May 42.5 option in the next day or so. Tomorrow I'll be watching it closely and, more than likely make my move.
If my logic doesn't agree with yours, let me know.
G' day Mate,
Aussie
Verylong...To avoid a TOS, I'll have to continue this on the OPTIONS TRADING Board. The TOU Refresher specifically states, "Any off-topic discussion is a violation of TOU" Matt's been good to me and I don't want that to change. Plus there's another tip over there. Once in a while is okay but lately we've been stretching it a bit.
G' day Mates
Aussie
Here's a good call.
Cigna Corp. (CI : CI) on Wednesday declared a 3-for-1 stock split, to be distributed June 4 to shareholders of record as of May 21. The Philadelphia-based healthcare company also said it is raising its quarterly dividend 20%, payable July 10 to shareholders of record as of June 12.
2-1, 3-1 and 4-1 stock splits often have pre-split run ups. Then about a week before the split it's time to sell the call. Wait until after the split and buy a short term call of a month or two. Again the stock goes up for a bit and then pulls back. In a case like Cigna's it is also then a good buy to get calls six monhts out and watch is it goes bask up . Splits have a tendency to seek their pre split levels or near it. Cigna's current price is $153.42. Prior to the split it should be around $165. Of course after the split the PPS would be around $55 per share. The stock shouldn't have much of a problem going to around $75 and settling for a while before slowing continuing its upward trend.
Something to think about.
G' day Mates,
Aussie
Calls on the current month are tough ones to do. What reasoning do you use to get out, as it is also coming within the 30 day expiration period? Thanks.
G' day Mate,
Aussie
ERIC May 42.5 calls are doing just fine.
G' day Mates,
Aussie
WMS To Report Fiscal 2007 Third Quarter Results on May 3 and Host Conference Call and Webcast. good companies like this usually see aboast in their PPS right before the results are released. Could be a good call play.
G' day Mates,
Aussie
Murgur...Glad to hear it. Now try visiting it once in a while. LOL.
G' day Mate,
Aussie
Verylong & Mugur...You may also want to check on OPTIONS TRADING Board.
You're welcome any time.
G' day Mates,
Aussie
DNDN is one you might want to do a collar on and the reasoning:
In late May 2006, sheep-like investors piled into shares of Pozen (POZN) with grandiose expectations for outright FDA approval for Trexima, a drug for the acute treatment of migraine. But all wasn’t good for the “sheep,” as the FDA didn’t share in their confidence. Instead, the FDA issued an unexpected June 2006 approvable letter that sent the stock plummeting from about $16 to less than $6.
Could this be the fate of Dendreon on May 15, 2007? Truth is, it could very well be.
20 days and counting… that’s how much time the FDA has remaining on its legal deadline to make a decision that’ll make or break Dendreon. Sure, the company scored big points when a panel of FDA advisers recommended that Provenge (a prostate cancer drug) be approved, but you’re dealing with the unpredictability of FDA politics here, and the fact that approval may have already been priced in.
In my honest opinion, buying this stock ahead of the decision may welcome more trouble than it’s worth. We’re not looking for the FDA to fully reject Provenge. What we are looking for is an approvable FDA letter, which will say that the drug will be approved if conditions are met. And that, my friends, could result in a horrifying gap down.
It doesn’t help that, according to Forbes.com, “Dendreon’s application to the FDA contains two late-stage studies with a combined total of 225 patients. Both studies missed their main goal… and the FDA tends to toss out studies that don’t make their main goal.”
Plus, the drug doesn’t come without criticism. Remember, four of the 17 panelists did not green-light approval. Howard Sher, for one, a urological oncologist, says that the FDA cannot approve the drug based on current data and that approval should be deferred.
In my opinion, there’s a high likelihood that the FDA’s decision will burn Dendreon bulls. I don’t want you to be one of them. We’re looking for an approvable letter, which could result in a gap down by May 15, 2007.
Ian L. Cooper
Editor, Death Cross Trader
---------------------------------
G' day Mates,
Aussie
Verylong...Avanir right now is very perplexing. Where will the stock be in 3 months? 6 months? And 1-2 years? We all have a better shot at guessing where we'll be in those time spans and, whether or not our kids and grand kids will see Santa, the Easter Bunny and the Tooth fairy. However, I'll give it a go.
First Avanir has a conference call coming up on May 9th. A good guess is the stock will ride up a little before than. Take advantage of the calls and sell them right before the web cast. Avanir will release complete financial results for the three and six months ended March 31, 2007. Any one knows that Avanir has not had a stellar year and should report an increase in losses due to their R & D expenses, despite the fact they had to lay off some personnel. The only catch is what will they show as revenues from FazaClo® (expected net revenues of approximately $4.1 million are predicted). If revenues come in higher, then the PPS could increase by $1.50 for the short term. That scenario is unlikely since the revenue projections appear to have been supplied by Avanir themselves.
In six months with no meaningful PRs, the stock should settle down to around $3 or lower. Unfortunately, the last PR on diabetic neuropathic pain isn't strong enough to keep the PPS up in light of the company's own expectations, "The Company expects this to be the first of two pivotal studies required for the approval of Zenvia in the treatment of diabetic neuropathic pain." One study could last six months or longer. Two is any one's guess.
1-2 years. Well, the above just about takes in from 3 months to one year. Two years and Zenvia comes into focus again for the treatment of IEED and that certainly will get investors excited again.
Now I skipped the limbo period, which is the time frame between one and two. This will largely depend on how sales of FazaClo do. If they keep increasing as expected, then Avanir could see around $10 in that time. Is there a sleeper in this period? Not in Avanir's pipeline, as all other items in Avanir's pipeline are in phases II or lower.
Outside of their pipeline? Possibly. And, it is in their establishing a cGMP manufacturing process and to test efficacy of the fully human monoclonal antibody treatment against inhalation anthrax in non-human primates. If successful, these pre-clinical studies can be used to support the filing of an investigational new drug application (IND) for AVANIR’s potential anti-anthrax drug candidate, AVP-21D9. This is being done with funding from National Institutes of Health/National Institute of Allergy and Infectious Disease (NIH/NIAID) under its Cooperative Research Partnerships for Biodefense program. Avanir has been involved with this since the first anthrax scare. Remember, anthrax isn't much of an issue; however, Avanir has alluded in the past that their findings are aimed at other allergy and infectious diseases and biodefenses. To say the lest, this program is way over due.
Hope this helps. Or, at best, I put you to sleep and you can't remember it all. LOL
G' day Mate,
Aussie
Verylong & Whitewlof...I have been with and followed Avanir since 1999 and, you can rest assure it doesn't operate on any rumors from Avanir.
G' day Mates,
Aussie
Avanir Pharmaceuticals expects higher 2nd-quarter profit to narrow its loss
AP
ALISO VIEJO, Calif. (AP) - Avanir Pharmaceuticals said Monday it expects an operating loss of between $11 million and $12.5 million during its fiscal second quarter.
The company said the figure excludes any downsizing costs from its San Diego research facilities. In March, the company ended research collaborations on two drugs with AstraZeneca Plc. and said it expects to close its San Diego facility by the end of the year. During the same period in 2006, the Avanir posted an operating loss of $13.9 million and a net loss of $13.4 million, or 43 cents per share.
Avanir said it expects revenue of about $6.1 million during the quarter, including about $4.1 million in sales of FazaClo. The company's fiscal second-quarter ended March 31. During the second quarter of 2006, revenue totaled $2.5 million.
Shares of Avanir rose 40 cents, or 9.1 percent, to $4.80 on the Nasdaq Stock Market in morning trading. The stock has traded between $1.07 and $14.64 over the last 52 weeks.
-------------------
G' day Mates,
Aussie
Make mine a decaf with equal. :)
G' day Mate,
Aussie
Tina Marie...That deserves a people mark.
G' day Mate,
Aussie
AVANIR Pharmaceuticals Invites Investors to Second Quarter Conference Call and Provides Preliminary Results for Second Quarter and Business Highlights
AVANIR Pharmaceuticals (NASDAQ:AVNR) today provided preliminary results and a business update for the second quarter and announced that it will release complete financial results for the three and six months ended March 31, 2007 before market open on Wednesday, May 9, 2007. Keith Katkin, President and Chief Executive Officer, Michael Puntoriero, Senior Vice President and Chief Financial Officer, and Randall Kaye, M.D., Senior Vice President and Chief Medical Officer, will host an investment community conference call that same day at 8:00 a.m. Pacific time / 11:00 a.m. Eastern time to discuss those results and answer questions.
Investors are invited to listen to the live webcast by visiting AVANIR's corporate website at www.avanir.com. To listen to the live call, please go to AVANIR's website prior to the start of the call to register, download and install the necessary audio software.
A webcast replay will be available on AVANIR's website for 30 days, and a telephone replay will be available through May 14, 2007, by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering the conference ID number 5305269.
Preliminary Results
Preliminary results for the quarter ended March 31, 2007 are provided below, along with a summary of certain business highlights for the quarter:
Total net revenues for the quarter are expected to be $6.1 million, including FazaClo® net revenues of approximately $4.1 million. FazaClo net wholesaler shipments for the quarter ended March 31, 2007 were approximately $4.2 million.
Estimated operating loss for the quarter is expected to be in the range of between $11.0 million and $12.5 million, excluding the impact, if any this quarter, from the downsizing of the San Diego research facilities.
Raised net proceeds of approximately $6.9 million from the sale of 3.2 million shares of common stock into the open market under the offering prospectus on file with the SEC.
Total outstanding notes under the Alamo Pharmaceuticals purchase agreement at March 31, 2007 was $22.3 million. This amount increased over the prior quarter by a net amount of $600,000 due to the issuance of an additional $2 million note following the achievement of a revenue-related earn out milestone. This increase was partially offset with the payment to the note holder of $1.4 million, generated from equity offering proceeds.
Completed the quarter with cash, cash equivalents, investments in securities and restricted cash of $8.7 million.
Other Business Highlights
Announced that after a meeting with officials of the U.S. Food and Drug Administration (FDA) in late February 2007, that AVANIR will conduct an additional trial in patients with IEED to confirm that a proposed lower does is safe and effective. Also announced that the Company has agreed to initiate certain preclinical and clinical pharmacology studies involving Zenvia™. The Company is currently working with the FDA on clinical trial design.
Announced that Keith Katkin, formerly Sr. VP of Sales and Marketing, was elected President and CEO and appointed to the Board of Directors following the departure of Eric Brandt. The Company also announced that Randall Kaye, M.D., formerly Vice President, Clinical and Medical Affairs, was elected Senior Vice President and Chief Medical Officer.
Announced that the Company is in discussions with several parties that have expressed interest in potentially acquiring certain Company assets, including FazaClo and several investigational compounds. These discussions remain ongoing, although no definitive terms have been reached for any transaction.
Announced that Novartis plans to advance the lead candidate for the Macrophage Migration Inhibitor Factor (MIF) program, AVP-28225, towards clinical development. Also, that AVANIR's research collaboration agreements with AstraZeneca and Novartis will end in the third fiscal quarter and that the Company will receive no additional revenues from these collaborations once they terminate.
Further, the Company announced that it has initiated planning to reduce ongoing operational costs associated with the loss of revenues from the collaboration arrangements and that the Company expects to reduce headcount in San Diego and seek to sublease a substantial portion of its remaining space in San Diego. The Company expects to terminate approximately 20 employees in San Diego during the current quarter and is in discussions regarding the proposed sublease of its San Diego lab facilities.
Reported that the audit committee of the Board of directors dismissed Deloitte & Touche LLP as the Company's independent auditors and has engaged KMJ Corbin & Company to serve in that capacity.
Following the end of the quarter, AVANIR announced positive results of the Phase III study for Zenvia in diabetic neuropathic pain.
Business Outlook
As previously reported, we plan to raise additional capital to fund operations, including clinical activity required for the commercialization of Zenvia. Although no option for raising additional capital is being ruled out at this time, our goal remains to minimize shareholder dilution. Management is moving aggressively to implement cost cutting and restructuring measures. The Company is targeting an annual net cash burn rate of $20 million or an average of $5 million per quarter, excluding the costs associated with a second Zenvia trial for the treatment of diabetic neuropathic pain.
About AVANIR
AVANIR Pharmaceuticals is focused on developing, acquiring and commercializing novel therapeutic products for the treatment of chronic diseases. AVANIR's products and product candidates address therapeutic markets that include the central nervous system, inflammation and infectious diseases. AVANIRÂ currently markets FazaClo®, the only orally-disintegrating formulation of clozapine for the management of severely ill schizophrenic patients who fail to respond adequately to standard schizophrenic drug treatments. FazaClo is also indicated for reducing the risk of suicidal behavior in patients with schizophrenic or schizoaffective disorder. For full prescribing information and important safety information regarding FazaClo, please visit www.fazaclo.com., AVANIR's lead product candidate for the treatment of involuntary emotional expression disorder (IEED), Zenvia™, is the subject of an approvable letter from the FDA. AVANIR has licensed certain compounds to Novartis International Pharmaceutical Ltd. for the treatment of inflammatory disease. The Company's first commercialized product, Abreva®, is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.
Forward Looking Statements
Statements in this press release that are not historical facts, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," or similar statements, are forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from the future results expressed or implied by such statements. There can be no assurance that the Company will receive FDA regulatory approval for Zenvia for any indication. Final review decisions made by the FDA and other regulatory agencies are often unpredictable and outside the influence and control of the Company, and it is possible that the FDA could disagree with the Company's interpretation of clinical trial results. Risks and uncertainties also include the risks set forth in AVANIR's most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and from time-to-time in other publicly available information regarding the Company. Copies of this information are available from AVANIR upon request. AVANIR disclaims any intent to update these forward-looking statements.
To be included on AVANIR's e-mail alert list; click on the link below or visit AVANIR's website: http://www.b2i.us/irpass.asp?BzID=958&to=ea&s=0
--------------------------------
G' day Mates,
Aussie
AVANIR PHARMACEUTICALS INC
Weekly Commentary
Our system posted BUY CONFIRMED. The previous SELL recommendation that was confirmed was made on 10.27.2006 (175) days ago, when the stock price was 8.5900 . Since then AVNR has fallen -48.78% .
BUY-IF is confirmed by a white candlestick with a higher open. The confirmation price is taken as this week's open ( 1.2500 ) according to Rules of Confirmation.
Patience pays off. The market wavered a week but finally confirmed the recent bullish formation. The dose of the previous week was not enough for a BUY-IF confirmation but this week it is. The week opened with a gap up and the price activity resulted in a close higher than the open. This is a valid confirmation criterion. The market is now ready for a bullish move.
We hope that you bought this stock. You should watch the upward gap in the beginning of the week, closely monitor the current confirmation status posted daily, feel the bullish tendency of the market making sure that prices stay over the opening price and then go long. Your benchmark was the opening price of the upward gap.
If you bought, continue to hold this stock until the confirmation of the next SELL-IF signal. You are on safe grounds as long as the future prices continue to trade above the benchmark price. What to do if you did not buy? Maybe, you did not have time to follow the sessions during the week or you simply delegated the delicate job of confirmation to us. Well it is a bit late, but not too late. You may still find suitable prices for buying in the following sessions.
The market is currently cold for short-sellers. Avoid any short sales and cover the short positions if there are any.
Data provided by: End of Day Data
BUY
CONFIRMED
4.4000
+3.2000 +266.67%
Stock Quote
Week's Close 4.4000
Previous Weekly Close 1.2000
Previous Weekly Open 1.2500
Change +3.2000
% Change +266.67%
Volume 184,860,400
Stock Activity
Week's Open 1.2500
Week's High 6.7500
Week's Low 1.2000
20-Week Close M.A. 2.1185
50-Week Close M.A. 4.8494
20-Week Volume M.A. 13,234,232
ABOVE BY: WEEKLY AMERICAN BULLS.COM
-------------------------------
G' Day Mates,
Aussie
James...How are you. Got the one email and I responded to it today. Hopefully there won't be any more problems. The second one seems to be caused as there was an "@" after my email address.
I like OneVoice but they are a loooooong shot.
AVVNR did good last week. Have to see how the market treats them this week.
G' day Mate,
Aussie
Encysive Pharmaceuticals Announces Conference Call to Discuss First Quarter 2007 Results
HOUSTON, April 18, 2007 (PRIME NEWSWIRE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) will hold an investor conference call on Monday, May 7, 2007 at 8:00 a.m. ET to discuss its first quarter 2007 financial results.
You may access the call either through the call-in number below or through the audio webcast. The access number for the call is:
Number: (612) 332-0107
Passcode: Encysive Pharmaceuticals
This call is being webcast and can be accessed via Encysive's web site at www.encysive.com.
A replay of the webcast will be available on the Company's web site through June 7, 2007. Additionally, a replay of the call will be available until Friday, May 11, 2007 at 11:59 p.m. ET. The call replay can be accessed by calling:
Number: (320) 365-3844
Access Code: 871348
About Encysive Pharmaceuticals
Encysive Pharmaceuticals Inc. is a global biopharmaceutical company engaged in the discovery, development and commercialization of novel, synthetic, small molecule compounds to address unmet medical needs. Our research and development programs are predominantly focused on the treatment and prevention of interrelated diseases of the vascular endothelium and exploit our expertise in the area of the intravascular inflammatory process, referred to as the inflammatory cascade, and vascular diseases. To learn more about Encysive Pharmaceuticals please visit our web site: www.encysive.com.
The Encysive Pharmaceuticals Inc. logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=843
--------------------------
G' day Mates,
Aussie
Might want to consider calls on AAPL this week.
Jim Cramer said the one tech stock he's looking at right now is Apple (AAPL - Cramer's Take - Stockpickr - Rating) ahead of Wednesday's postclose earnings report. Cramer said this is the last quarter before Apple's release of its much-anticipated iPhone, and buying the stock at a recent $90 is a good move considering the weakness of the competition. Cramer said Nokia (NOK - Cramer's Take - Stockpickr - Rating) has tacked on 6 points from its January lows largely because Motorola (MOT - Cramer's Take - Stockpickr - Rating) is sputtering and misfiring.
-------------------
Just a thought.
G' day Mates,
Aussie
nlightn...Was hoping one of the others would tackle your question. I am fairly new to the options game and am not sure of the answer. I've had it happen a couple of times and even this month with another stock. However, it didn't happen until today. The others also happened at or near the end of the month. This leads me to think it may be related to the timing left on the options. As time erodes, so does the premium. That just might be the case. If I find out any other reason, I'll be sure to pass it on.
G' day Mate,
Aussie
ERIC reported:
Updated:2007-04-20 09:18:03
Sony Ericsson more than doubles profit in 1st quarter
By LOUISE NORDSTROM
AP
STOCKHOLM, Sweden (AP) - Mobile phone maker Sony Ericsson 's first-quarter earnings more than doubled on strong sales of its Walkman music handsets, the company said Friday.
Net profit came to euro254 million (US$346 million) in the first three months of the year, up from euro109 million in the same period last year. Sales rose 47 percent to euro2.93 billion (US$3.99 billion) from euro1.99 billion in the first quarter of 2006.
London-based Sony Ericsson, a joint venture of Japan's Sony Corp . and Sweden's LM Ericsson, said strong sales growth in Asia, Latin America and Europe helped its market share grow 2 percentage points to 8 percent.
"The company captured market share in these markets through low and mid-tier products such as the W300 and W200 Walkman phones and the K310 camera phone without undermining profitability," Sony Ericsson said.
However, the closely watched average selling price of Sony Ericsson's handsets dropped to euro134 (US$182) from euro149 in the first quarter of last year.
----------------------------------
So with that good report on the table, I decided to watch the ERIC shares with the intent of buying calls. Good thing I didn't, the stock started sliding on the opening bell. However, I decided to take a chance and buy some May 42.5 calls at $.30 to see if the stock bounces up at the end of the day. At that price, it's worth the risk.
G' day mates,
Aussie
Newspaper wrap-up 4-20-07: Starbucks trying to move into India
Posted Apr 20th 2007 9:20AM by Eric Buscemi
Filed under: Newspapers, Magazines, Internet, Google (GOOG), Starbucks (SBUX)
MAJOR PAPERS:
Heinrich von Pierer resigned as chairman of Siemens AG ADR's (NYSE: SI) supervisory board amid criminal bribery probes, reported the Wall Street Journal (subscription required).
OTHER PAPERS:
The Business Standard reported that Starbucks Corporation (NASDAQ: SBUX) has sent a revised application to operate single-brand retail stores in India.
------------------
G' day Mates,
Aussie
Mugur...Unfortunately, I don't want to be right on AVNR. However, facts are facts. Today so far before the bell is interesting. AVNR already has over a million shares traded. Should be fun.
You may want to check on ERIC calls for today.
G' day Mate,
Aussie
No surprise so far. I did state in post #816:
"I have followed Avanir since 1999 and have purchased stocks and options (puts & calls) and I guaranteed it will go back down and maybe even lower than your $3 to around $2.50.
The FDA still hasn't said "bo!" yet. Avanir shareholders know from Abreva and Neurodex how important the FDA is. Until Avanir submits to them for approval, the stock will rock back and forth. It'll be to traders advantage to watch the swings."
Didn't take long for the swings. More to come.
G' day Mates,
Aussie
Here's a dumb and dumber article.
On The Move For Thursday, April 19
Jennifer Lee, 04.19.07, 1:13 PM ET
Avanir Pharmaceuticals (nasdaq: AVCI - news - people ) led the pack yesterday, and its shares continue to climb today. Investors are impressed by its new drug Zenvia, which treats nerve pain in diabetics
http://www.forbes.com/markets/2007/04/19/avici-spansion-etrade-markets-cx_jal-0419onthemove.html?par....
First Jennifer sticks her foot in her mouth without checking that Avanir's climb was on a slippery ladder. Now the stock is down about $.05. When the article was written at 1:13 PM, the stock was really down on the big slide. They should have waited a bit. Then someone didn't bother to proof read the article to see they had the wrong symbol.
Good reporting can be hard to come by.
IMO.
G' day Mates,
Aussie
Appears an avalanche has really snowballed. From a high of $6.75 to $5.36. Puts are looking good right now. However, late traders usually have something to say. Should be interesting.
G' day Mates,
Aussie
For those of you not familiar with Diabetic Neuropathic Pain and the significance of Avanir's latest PR:
Fact: Over 18 million Americans have diabetes. And up to half of them will have some form of nerve damage due to their diabetes.
Diabetic neuropathy, if not treated, and there is no cure, can lead to severe complications. This would be a blessing to diabetics.
Peripheral neuropathy:
This type of neuropathy damages nerves in the arms and legs. The feet and legs are likely to be affected before the hands and arms. Many people with diabetes have signs of neuropathy upon examination but have no symptoms at all. Symptoms of peripheral neuropathy may include
numbness or insensitivity to pain or temperature
a tingling, burning, or prickling sensation
sharp pains or cramps
extreme sensitivity to touch, even a light touch
loss of balance and coordination
These symptoms are often worse at night.
Peripheral neuropathy may also cause muscle weakness and loss of reflexes, especially at the ankle, leading to changes in gait (walking). Foot deformities, such as hammertoes and the collapse of the midfoot, may occur. Blisters and sores may appear on numb areas of the foot because pressure or injury goes unnoticed. If foot injuries are not treated promptly, the infection may spread to the bone, and the foot may then have to be amputated. Some experts estimate that half of all such amputations are preventable if minor problems are caught and treated in time.
G' day Mate,
Aussie
verylong4PMTI...Thank you. Now what you stated makes more sense. G' luck with your plan.
One of my AVNR purchases is a Jan08 10 calls at $.45. Wasn't home when the stock hit $6.75 and missed an opportunity to more than double.
G' day Mate,
Aussie
verylong4PMTI...Enlighten me! You do this through a broker??? Why not through an on line firm like Scottrade and save more money on the stock. I assume you buy your options on line through a firm similar to OptionsXpress. Thank you.
G' day Mate,
Aussie
Person Marks to the following:mugur, Greedy Fox, JDUB, Veritas77, verylong4PMTI & fastlizzy.
G' day Mates,
Aussie
JDUB...WOW! More than I expected. AVNR is going to make me rethink things a little. Up as high as $6.75 this A.M. Now at $6.10. Might be dropping. Keeping a close eye on it.
G' day mate,
Aussie
mugur...Agree with you there. The charts in no way support an up trend. I use a 7,18 & 30 SMA with OBV, Volume+ and Williams%R and there is nothing there to say the trend is heading upward. Have to wait and see how this plays out. My feeling is it's definitely very short term. However, I do hope I'm wrong.
G' day Mate,
Aussie
fastlizzy...After the excitement of this PR, then what really do investors and potential investors have to look forward to? Nothing until another PR or an FDA submission.
Avanir's history is that it usually retreats. I did say, "I guaranteed it will go back down and maybe even lower than your $3 to around $2.50." Not that it would definitely go down; but, realistically with no PR or other solid information in the meantime, then $2.50 is a possibility. Not a definite, just "maybe."
And, if you go to some of the other boards, you just may find that others think lower and are more definite about their guesses.
Just my opinion.
G' day Mate,
Aussie
fastlizzy...No one even hinted the FDA approval was around the corner, so I don't know where you got that or where you're coming from. Shareholders of Avanir know very well from two experiences, that the FDA approval is not guaranteed in any way. Avanir must request approval and before that, the stock will have its ups and downs. Then all hold their breath waiting for the FDA. So far the FDA has not been very kind to Avanir.
The $18 was right after the reverse split. I had sold shares before and after the split. Can't complain, Avanir has done well for me.
G' day Mate,
Aussie
mugur...I have followed Avanir since 1999 and have purchased stocks and options (puts & calls) and I guaranteed it will go back down and maybe even lower than your $3 to around $2.50.
The FDA still hasn't said "bo!" yet. Avanir shareholders know from Abreva and Neurodex how important the FDA is. Until Avanir submits to them for approval, the stock will rock back and forth. It'll be to traders advantage to watch the swings.
G' day Mate,
Aussie
Surf...Thanks for posting the PR. Just read it and was about to post it when I saw your post.
G' day Mate,
Aussie
Starbucks will still be bigger than McDonald's
Posted Apr 16th 2007 9:20AM by Georges Yared
Filed under: Before the bell, Forecasts, Competitive strategy, Starbucks (SBUX), McDonald's (MCD)
McDonald's Corp. (NYSE: MCD) announced that its same store sales for March 2007 were up 8.2% and its first quarter sales were up 6.3% versus last year. Both numbers are impressive and McDonald's stock is reacting very well. The shares closed Friday at $47.64 and a couple of firms upped their 12-month price targets to $52 and $58. These targets imply upside to the stock price of 10-22% from here. A potentially good year lies ahead for the world's largest restaurant chain.
But if you want to invest some money for the next couple of years and you want exposure to the space, I think the far better investment for growth is Starbucks Corp. (NASDAQ: SBUX). Even with momentum building in the McDonald's story, at the end of the day, consensus estimates call for revenue growth of 5-6% for 2008 over 2007, and barely 10% earnings growth for 2008 over 2007. The company is going through a growth spurt, with newer menu items such as snack wraps, and some very good publicity for its coffee products. There has been a growing debate about whose coffee is better, Starbucks or McDonald's. The choice is a personal one and some customers do visit McDonald's just for the coffee, but they are in the minority.
McDonald's will experience pockets of growth through varied menu offerings, coffee debates and better regional management that they have been quietly putting into place. But it is not a growth story. McDonald's has 31,045 units strategically placed in 118 countries. They have virtually saturated the markets they serve. McDonald's has been a pioneer in the fast food industry, the industry leader by a wide mile. But growing the concept at a 20% sustainable level is not in the cards. Investors these past 12 months have done well with their shares appreciating nicely from a 52-week low of $32 to this level of $47-48.
But where do we go from here? True growth investing is to be involved with a terrific story, with great management, but the addressable market has to show room for large and unencumbered expansion. McDonald's is not facing this last option for the next 3-5-7 years. Starbucks is.The baseball analogy is McDonald's is in the 9th inning and hoping for extra-innings. Starbucks is in the 3rd inning with plenty still to play.
With about 11,000 units in place worldwide, Starbucks has room to nearly four-fold these unit numbers to 40,000+. Starbucks, more importantly has the bandwidth to expand its product offerings. As the store units are far from saturation, so is the in-store product offering. Starbucks has yet to realize what a fully mature store can yield in gross revenues. With books, CD's, DVDs and other novelty items placed within the store, the potential to grow the same store sales, as well as the overall units, provides investors with a growth story for the next 5+ years.
I think investors looking at both names are better off in Starbucks these next 3-7 years. With sustainable growth of revenues and earnings of 20%+ for Starbucks, the shares have a great opportunity to triple to quadruple in value these next 5 years. McDonald's will keep pace with the S&P 500 at least, and show signs of occasional acceleration, but the sustainability is questionable.
Georges Yared is the CIO of Yared Investment Research.
------------------------
G' day Mates,
Aussie
RJ...I bought SBUX shares before and after the last split and plan to hold on to them for while. Sales figures from overseas have yet to have an impact on the PPS and I for one feel they will.
G' day Mate,
Aussie